Risk Factors for Asymptomatic Ventricular Dysfunction in Rheumatoid Arthritis Patients
Table 2
Comparison of clinical and biochemical characteristics between rheumatoid arthritis patients with and without ventricular dysfunction.
Variables
Ventricular dysfunction
No ventricular dysfunction
Age (years)
0.02
Habitual weight (kg)
0.36
Body mass index (kg/m2)
0.83
Rheumatoid arthritis evolution time
0.11
Cancer (%)
9.6
14
0.51
Coronary artery disease (%)
45.3
11.9
<0.0001
Obesity (%)
21.2
25
0.65
Diabetes (%)
26.4
9.3
0.03
Dyslipidemia (%)
11.5
32.6
0.01
Hypertension (%)
56.6
54.5
0.84
Nephropathy (%)
15.1
14
0.87
Albumin (mg/dL)
0.38
Hemoglobin (g/dL)
0.39
Hematocrit (%)
0.39
Total cholesterol (mg/dL)
0.047
c-LDL (mg/dL)
0.005
c-HDL (mg/dL)
0.78
Triglycerides (mg/dL)
0.04
DAS28 questionnaire
0.18
Rheumatoid factor UI/dL
96.5 (63.9–631.7)
37 (20.8–220.8)
0.03
Anti-CCP antibody
264 (23–136.5)
114 (18.9–784.3)
0.34
C-reactive protein
1.65 (0.89–2.85)
1.03 (0.57–4.08)
0.34
ESR (mm/hr)
29 (18–48.8)
33 (18.8–57)
0.5
Functional capacity
Stage 1
18 (36)
24 (53.3)
Stage 2
24 (48)
12 (26.7)
0.13
Stage 3
8 (16)
8 (17.8)
Anti-CCP: anticyclic citrullinated peptide antibodies; ESR: erythrocyte sedimentation rate. Data are expressed as %, mean ± standard deviation, or median (percentile 50–75).